Trending Topics in Gastroenterology | GastroAGI

Comparative Efficacy and Safety of Endoscopic Modalities for Colorectal Cancer Screening in IBD

The comparative efficacy and safety of endoscopic modalities for colorectal cancer (CRC) screening in patients with inflammatory bowel disease (IBD) have been thoroughly investigated in the modern high-definition (HD) endoscopy era. Below is a detailed analysis based on current evidence: --- ### **1. Background: Elevated CRC Risk in IBD** - Patients with long-standing ulcerative colitis and colonic Crohn’s disease are at significantly increased risk for colorectal cancer. - Regular surveillance is critical to detect dysplasia (precancerous lesions) early and improve outcomes. --- ### **2. Study Overview: High-Definition Endoscopy Era** - A network meta-analysis of 26 randomized controlled trials (RCTs) involving 4,159 patients with IBD was conducted. - The primary outcome was the detection of at least one dysplastic lesion per patient. - The analysis compared multiple HD endoscopic modalities, with HD white light endoscopy (HD-WLE) serving as the reference standard. --- ### **3. Findings: Efficacy of Endoscopic Modalities** #### **a. High-Definition White Light Endoscopy (HD-WLE):** - Used as the reference standard for comparison. - Found to be effective but not the most sensitive modality for dysplasia detection. #### **b. High-Definition Dye-Based Chromoendoscopy (HD-CE):** - Demonstrated a **small but measurable improvement** in dysplasia detection compared to HD-WLE. - The magnitude of benefit ranged from trivial to moderate, with low-certainty evidence based on GRADE criteria. - This technique involves applying dyes (e.g., methylene blue or indigo carmine) to enhance mucosal visualization. #### **c. Virtual Chromoendoscopy (e.g., Narrow Band Imaging):** - Did not show significant improvement in dysplasia detection over HD-WLE. - The evidence suggests that virtual chromoendoscopy may not be superior for surveillance in IBD patients. #### **d. Full-Spectrum Endoscopy:** - No clear difference in dysplasia detection compared with HD-WLE due to imprecise estimates. - Further studies are needed to clarify its effectiveness. #### **e. Autofluorescence Imaging:** - Showed very low-certainty evidence and no reliable advantage in dysplasia detection. - This technique remains investigational in the context of IBD surveillance. #### **f. HD-WLE with Segmental Reinspection:** - Inconclusive benefit due to very low-certainty evidence. - This approach involves re-examining specific segments of the colon for missed lesions. #### **g. Targeted Biopsies:** - No modality demonstrated high-certainty superiority for dysplasia detection from targeted biopsies. - Targeted biopsies remain a cornerstone of surveillance but are dependent on the quality of visualization. #### **h. Random Biopsies:** - Dysplasia detection from random biopsies was rare, limiting their utility in meaningful comparisons. - This finding aligns with the growing preference for targeted biopsies over random sampling. --- ### **4. Safety Profile Across Modalities** - Serious adverse events were **rare** across all endoscopic modalities, indicating an acceptable safety profile for CRC surveillance in IBD patients. --- ### **5. Key Takeaways:** - **HD Dye-Based Chromoendoscopy (HD-CE)** offers a modest improvement in dysplasia detection over HD-WLE but with low-certainty evidence. - Other advanced techniques (e.g., virtual chromoendoscopy, full-spectrum endoscopy, autofluorescence imaging) did not demonstrate consistent superiority over HD-WLE. - Dysplasia detection from random biopsies was infrequent, reinforcing the importance of high-quality mucosal visualization and targeted biopsies. - The choice of modality should balance efficacy, availability, cost, endoscopist expertise, and practical feasibility. --- ### **6. Implications for Guidelines and Clinical Practice** - These findings directly inform guidelines for CRC surveillance in IBD patients. - While HD dye-based chromoendoscopy may be preferred for its slight advantage in dysplasia detection, HD-WLE remains a widely used and effective option. - No single modality demonstrated clear, consistent superiority, emphasizing the need for individualized decision-making in clinical practice. --- ### **7. Recommendations for Clinical Decision-Making** - **Patient Factors:** Consider disease duration, severity, and prior dysplasia history. - **Endoscopist Expertise:** Techniques like HD dye-based chromoendoscopy require training and experience. - **Resource Availability:** Not all centers may have access to advanced modalities like virtual chromoendoscopy or autofluorescence imaging. - **Cost and Feasibility:** HD-WLE is cost-effective and widely available, making it a practical choice in many settings. --- ### **Conclusion** While HD dye-based chromoendoscopy offers a slight improvement in dysplasia detection, the overall differences between modalities are modest. HD-WLE remains a reliable and accessible option for CRC surveillance in IBD patients. Future research is needed to clarify the role of emerging technologies and optimize surveillance strategies.

Systematic endoscopic characterization of synchronous esophageal, gastric, and colorectal involvement in multisystem Langerhans cell histiocytosis

Systematic endoscopic characterization of synchronous esophageal, gastric, and colorectal involvement in multisystem Langerhans cell histiocytosis (LCH) provides critical insights into the rare and under-recognized gastrointestinal (GI) manifestations of this disease. Below is a detailed overview of the findings and implications: ### 1. **Rarity and Multisystem Nature of LCH:** - Adult-onset LCH is uncommon, and gastrointestinal involvement is particularly rare. - LCH is a multisystem disease that can affect various organs simultaneously, including the oral cavity, lungs, and GI tract. ### 2. **Endoscopic Findings Across the GI Tract:** - **Esophageal Involvement:** - Lesions in the esophagus were characterized by distinct patterns, including: - Raised plaques with central depressions. - Radial telangiectasia. - Barnacle-like satellite nodules. - These findings are unique and contribute to the recognition of esophageal LCH. - **Gastric Involvement:** - Gastric lesions presented with a diverse range of appearances, such as: - Ulcerative defects. - Firm submucosal protrusions with surface erosion. - These findings highlight the variability of gastric LCH manifestations. - **Colorectal Involvement:** - Colonic lesions appeared as clustered submucosal masses, with a predilection for the ileocecal and sigmoid regions. - The submucosal nature of these lesions often made them difficult to detect on superficial examination. ### 3. **Submucosal Predominance and Diagnostic Challenges:** - Many LCH lesions were predominantly subepithelial, with intact overlying mucosa. - This submucosal location complicates the ability to diagnose the disease through superficial biopsies. - A novel endoscopic observation, termed the "mucosal fragmentation sign," was identified during resection. This sign refers to fragile mucosa overlying tumor tissue, likely caused by pressure from expanding submucosal infiltration. ### 4. **Histologic and Molecular Confirmation:** - Diagnosis of LCH relies on histological confirmation of Langerhans cells, which are positive for markers such as: - CD1a. - S100. - Langerin. - Additionally, the presence of the BRAF V600E mutation supports the neoplastic nature of adult LCH. ### 5. **Importance of Deep Biopsies:** - Given the submucosal predominance of LCH lesions, deep biopsies are essential to obtain diagnostic tissue. - Superficial biopsies may fail to capture the underlying pathology, leading to missed or delayed diagnosis. ### 6. **Imaging Limitations:** - Conventional imaging methods, including PET scans, often fail to detect mucosal or submucosal GI LCH lesions. - Endoscopic evaluation is therefore critical for identifying these lesions. ### 7. **Differential Diagnosis and Misdiagnosis Risk:** - GI LCH may mimic other conditions such as carcinoma, lymphoma, or inflammatory diseases. - This overlap increases the risk of misdiagnosis, emphasizing the need for heightened clinical awareness. ### 8. **Clinical Implications and Recommendations:** - **Proactive Endoscopy:** - Patients with confirmed LCH, even in the absence of digestive symptoms, should undergo systematic gastrointestinal endoscopy to detect potential GI involvement. - **Recognition of Endoscopic Patterns:** - Awareness of the characteristic endoscopic findings (e.g., raised plaques, submucosal masses, mucosal fragmentation) can facilitate earlier diagnosis in atypical cases. - **Multidisciplinary Approach:** - Collaboration between gastroenterologists, pathologists, and oncologists is crucial for accurate diagnosis and management. ### 9. **Significance of the Case:** - This case uniquely documents concurrent involvement of the esophagus, stomach, and colon in an adult patient with LCH. - It underscores the value of systematic endoscopic characterization in identifying widespread GI lesions that may not be apparent on imaging or present with overt symptoms. ### 10. **Conclusion:** - Systematic endoscopic evaluation is a vital diagnostic tool in detecting synchronous GI involvement in multisystem LCH. - Early recognition and deep biopsy of characteristic lesions can lead to timely diagnosis and appropriate management, improving outcomes for patients with this rare disease.

Endoscopic characterization of synchronous esophageal, gastric, and colorectal involvement in multisystem Langerhans cell histiocytosis

The endoscopic characterization of synchronous esophageal, gastric, and colorectal involvement in multisystem Langerhans cell histiocytosis (LCH) involves identifying specific patterns and features across the gastrointestinal (GI) tract. This is particularly important as GI involvement in adult-onset LCH is rare and often under-recognized. Below is a detailed description of the endoscopic findings and their implications: ### 1. **Esophageal Involvement** - **Appearance of Lesions**: The esophageal lesions in LCH typically present as raised plaques with central depressions. These plaques may also exhibit: - Radial telangiectasia (dilated blood vessels radiating outward). - Barnacle-like satellite nodules surrounding the primary lesion. - **Endoscopic Recognition**: These findings are distinct and can serve as a clue to the diagnosis, especially when combined with systemic manifestations of LCH. - **Challenges**: Superficial biopsies may not always capture diagnostic tissue due to the subepithelial nature of the lesions. ### 2. **Gastric Involvement** - **Lesion Diversity**: Gastric lesions in LCH can show a variety of morphologies, including: - Ulcerative defects with visible surface erosion. - Firm submucosal protrusions that may appear as masses beneath the mucosa. - **Diagnostic Difficulty**: The submucosal predominance of gastric lesions often complicates diagnosis, as the overlying mucosa may remain intact or only superficially eroded. - **Novel Endoscopic Sign**: The “mucosal fragmentation sign” has been described during endoscopic resection. This sign indicates fragile mucosa overlying tumor tissue, which fragments easily due to outward pressure from the submucosal tumor. ### 3. **Colorectal Involvement** - **Distribution and Morphology**: In the colon, LCH lesions often appear as clustered submucosal masses. These are particularly prominent in: - The ileocecal region. - The sigmoid colon. - **Endoscopic Features**: The lesions are primarily subepithelial, with intact or minimally altered mucosa, which can obscure their detection during routine endoscopy. - **Clinical Implications**: Colorectal lesions may mimic other conditions like carcinoma or lymphoma, increasing the risk of misdiagnosis. ### 4. **Submucosal Predominance** - Across the esophagus, stomach, and colon, a key feature of GI LCH lesions is their submucosal location. This makes superficial biopsies less effective, and deep biopsies are often required to retrieve diagnostic tissue. - **Histologic Confirmation**: Once tissue is obtained, the diagnosis is confirmed by identifying Langerhans cells that are positive for markers such as CD1a, S100, and Langerin. ### 5. **Endoscopic Challenges and Diagnostic Strategies** - **Imaging Limitations**: Conventional imaging and even PET scans may fail to detect these mucosal or submucosal lesions, emphasizing the critical role of endoscopy. - **Biopsy Technique**: Deep biopsies are essential for accurate diagnosis. The “mucosal fragmentation sign” can guide endoscopists in identifying areas for targeted sampling. - **Differential Diagnosis**: GI LCH lesions may mimic other diseases, including carcinoma, lymphoma, or inflammatory bowel disease. Recognizing the characteristic endoscopic patterns is key to avoiding misdiagnosis. ### 6. **Asymptomatic Involvement** - Extensive GI involvement can occur even in patients without digestive symptoms. This underscores the importance of proactive endoscopic evaluation in patients with confirmed LCH, regardless of symptomatology. ### 7. **Clinical Recommendations** - Patients with multisystem LCH should undergo a systematic and comprehensive endoscopic evaluation of the GI tract, even if they are asymptomatic. - Awareness of the specific endoscopic patterns associated with LCH can facilitate earlier and more accurate diagnosis, improving patient outcomes. ### Summary Endoscopic findings in synchronous esophageal, gastric, and colorectal involvement in LCH are distinct and can include raised plaques, submucosal protrusions, ulcerations, and clustered masses. The submucosal predominance of these lesions often necessitates deep biopsies for diagnosis. Recognizing characteristic endoscopic patterns, such as radial telangiectasia, barnacle-like nodules, and the mucosal fragmentation sign, is crucial for identifying GI LCH. Proactive endoscopic evaluation is recommended in all patients with confirmed LCH to detect potential GI involvement, even in the absence of symptoms.

ER-STER for cervical esophageal submucosal tumors via PEG

ER-STER (Endoscopic Retrograde Submucosal Tunnel Resection) represents an innovative approach to address the challenges of resecting cervical esophageal submucosal tumors (SMTs), which are difficult to access and treat using conventional endoscopic techniques due to the limited maneuvering space and proximity to the upper esophageal sphincter (UES). This method utilizes a retrograde approach via a percutaneous endoscopic gastrostomy (PEG) to overcome these limitations. ### Key Features of ER-STER: 1. **Concept and Purpose**: - ER-STER proposes accessing cervical esophageal SMTs retrogradely through a PEG tract, rather than the conventional oral route. - This approach aims to enlarge the working space and reduce manipulation near the sensitive UES region, minimizing discomfort for the patient. 2. **Procedure Overview**: - A submucosal tunnel is created from the anal side of the esophagus (via the PEG tract) to the tumor site. This tunnel allows en bloc resection of the SMTs in the cervical esophagus. - The retrograde access improves visualization and maneuverability, which are often compromised in oral-side tunneling due to space constraints. 3. **Steps Involved**: The ER-STER procedure consists of six key stages: - **Preoperative Evaluation**: Imaging and planning to determine tumor location and feasibility of PEG placement. - **PEG Creation**: A PEG is inserted in the left upper quadrant under imaging guidance, avoiding major vessels and the gastric antrum. - **Scope Insertion**: A gastroscope (slim or therapeutic) is introduced retrogradely through the PEG tract. - **Lesion Localization**: The tumor is identified using pre-marked clips or tattooing for orientation. - **Retrograde Tunnel Resection**: Submucosal injection creates a stable tunnel from the anal side, enabling precise tumor removal. - **Closure of Access Sites**: Both the PEG site and the submucosal tunnel are closed to prevent complications. 4. **Technical Considerations**: - **Submucosal Injection**: Performed 3–5 cm beyond the lesion on the anal side to ensure a stable tunnel. - **Orientation Control**: Clips or tattooing placed orally before the procedure prevent disorientation during retrograde tunneling. - **Insufflation Management**: Low-pressure carbon dioxide insufflation minimizes leakage and ensures safe lumen distension. - **Navigating Tight Spaces**: Techniques like gentle torque control, patient head elevation, and using slimmer scopes help overcome the narrow thoracic inlet. 5. **Advantages**: - Enlarged working space and improved visualization compared to oral-side STER. - Reduced manipulation near the UES, which decreases patient discomfort. - Preservation of overlying mucosa, minimizing the risk of postoperative strictures. - Better orientation during tumor resection, enhancing procedural accuracy. 6. **Safety Measures**: - Peri-procedural antibiotics to prevent stoma infection or mediastinal contamination. - Careful handling of the PEG tract and use of CO₂ insufflation to reduce perforation and leakage risks. - Expert endoscopic technique to avoid retrograde perforation. 7. **Potential Risks**: - PEG-related complications such as stoma infection, retrograde perforation, or mediastinal contamination. - Stricture formation, though less likely due to mucosal preservation. - Theoretical risks of procedural failure due to anatomical or technical challenges. ### Current Status and Future Directions: - **Validation Phases**: - ER-STER is still a theoretical concept and has not yet undergone preclinical or clinical testing. - Structured feasibility studies, including cadaveric testing, animal studies, and pilot human trials, are needed to assess its safety and efficacy. - Evaluation metrics will focus on en bloc resection rate, perforation risk, infection incidence, stricture formation, and procedural time. - **Limitations**: - The technique lacks preclinical or clinical data to confirm its effectiveness and safety. - Requires specialized training and expertise in retrograde tunneling and PEG-related procedures. - **Future Potential**: - ER-STER holds promise as a novel solution for difficult-to-access cervical esophageal SMTs. - If validated through rigorous studies, it could become a standard approach for these challenging cases, offering significant advantages over conventional methods. In summary, ER-STER via PEG introduces a groundbreaking retrograde technique for cervical esophageal SMTs, addressing the limitations of conventional oral-side endoscopic resection methods. While promising, it remains theoretical and warrants thorough preclinical and clinical validation to establish its feasibility and safety.

Robotic endoscopic resection

Robotic endoscopic resection refers to the use of robotic systems to perform advanced endoscopic procedures, particularly for the removal of large or complex lesions in the gastrointestinal (GI) tract. One of the most promising applications of robotic technology in this field is robotic endoscopic submucosal dissection (ESD), which aims to address the limitations of traditional ESD techniques. ### Background on Endoscopic Submucosal Dissection (ESD) ESD is a minimally invasive procedure used to remove large, superficial lesions (e.g., early-stage tumors or precancerous growths) from the GI tract, such as the esophagus, stomach, or colon. The goal of ESD is to achieve "en bloc" resection, meaning the lesion is removed in one piece. This provides several advantages: - **Better oncologic outcomes:** Complete removal reduces the risk of recurrence and allows for more accurate pathological analysis. - **Simplified follow-up:** Patients may require fewer follow-up procedures, such as colonoscopies. - **Environmental benefits:** Fewer follow-up procedures reduce the overall resource use and waste. Despite its benefits, traditional ESD is highly challenging. It requires advanced technical skills, has a steep learning curve, and is often performed without true triangulation (the ability to use multiple instruments independently in a coordinated way). This makes the procedure functionally "one-armed," limiting its precision and efficiency. ### Robotic Endoscopic Resection: A Solution to Current Limitations Robotic endoscopy, specifically robotic ESD, aims to overcome the technical barriers of traditional ESD. One example of a robotic system designed for this purpose is the **EndoMaster EASE system**, which was introduced in a phase II study led by Professor Chiu. This system incorporates: - **Two independently controlled robotic arms:** These arms allow for both cutting and traction, enabling true triangulation. - **A standard working channel:** This accommodates additional tools for the procedure. ### Key Findings from the EndoMaster EASE Study The study evaluated the performance of the EndoMaster EASE system in 45 cases involving colorectal lesions. The results were promising: - **Technical success rate:** 86% of cases were successfully completed using the robotic system. - **R0 resection rate:** Among successful cases, 83.8% achieved R0 resection, meaning no cancerous cells were left at the margins of the removed tissue. - **Dissection speed:** The median speed was 20.6 mm²/min for lesions with an average size of 34.5 mm. While these results do not yet surpass the performance of expert-level ESD or advanced traction techniques, the robotic system shows significant potential, particularly for less experienced endoscopists. The improved visualization and ability to perform triangulation could also shorten the learning curve for ESD. ### Advantages of Robotic ESD 1. **Improved precision:** The robotic arms allow for better control, cutting, and traction, which are critical for successful en bloc resection. 2. **Enhanced visualization:** High-definition imaging and better control of instruments improve the surgeon's ability to identify and remove lesions accurately. 3. **Shortened learning curve:** The intuitive design of robotic systems may make it easier for less experienced endoscopists to perform complex procedures. 4. **Potential for advanced procedures:** Robotic systems could enable new techniques, such as advanced suturing and closure of complex defects, which are difficult or impossible with traditional ESD. ### Challenges of Robotic Endoscopic Resection Despite its promise, robotic ESD faces several challenges: 1. **High cost:** Robotic systems are expensive to acquire and maintain, which may limit their adoption. 2. **Need for general anesthesia:** Unlike traditional ESD, which can sometimes be performed under sedation, robotic ESD often requires general anesthesia, increasing procedural complexity. 3. **Additional staffing requirements:** A robotic procedure may require a larger team, including specialized operators for the robotic system. 4. **Limited data for certain lesions:** Most studies, including the EndoMaster EASE study, have focused on lesions in the rectosigmoid region. Data on other areas of the GI tract are still limited. 5. **Environmental impact:** While fewer follow-up procedures may reduce waste, the environmental impact of the robotic systems themselves (e.g., energy use, disposable components) remains uncertain. ### Future Implications Robotic endoscopic resection represents a significant advancement in therapeutic endoscopy. As the technology continues to evolve, it has the potential to: - Make complex endoscopic procedures safer, more efficient, and more accessible. - Expand the range of lesions and conditions that can be treated endoscopically. - Reduce the dependence on highly experienced endoscopists, democratizing access to advanced care. However, widespread adoption will depend on addressing the current challenges, particularly the high cost and logistical demands. If these hurdles can be overcome, robotic endoscopic resection could revolutionize the field of therapeutic endoscopy, offering new possibilities for minimally invasive treatment of GI diseases.

The Boškoski–Costamagna ERCP Trainer

The Boškoski–Costamagna ERCP Trainer is an advanced simulation tool designed to aid novice trainees in developing their skills in Endoscopic Retrograde Cholangiopancreatography (ERCP), a complex endoscopic procedure used to diagnose and treat conditions affecting the bile ducts, pancreatic ducts, and gallbladder. This trainer provides a structured and controlled environment for hands-on practice, allowing learners to gain technical proficiency before performing procedures on actual patients. The use of the Boškoski–Costamagna ERCP Trainer offers significant advantages in the training pathway for ERCP. By incorporating simulation-based training early in the learning process, trainees can achieve enhanced outcomes, including: 1. **Improved Biliary Cannulation Success**: Practicing on the simulator allows trainees to refine their techniques for accessing the bile duct, a critical and challenging component of ERCP. 2. **Faster Procedure Times**: Simulation training helps users develop efficiency in performing ERCP, translating into reduced procedure times in real clinical settings. 3. **Accelerated Skill Development**: The hands-on experience provided by the trainer facilitates quicker mastery of essential ERCP skills, enabling trainees to progress toward competence more rapidly. The integration of the Boškoski–Costamagna ERCP Trainer into ERCP education programs is supported by evidence that it enhances trainee performance. By simulating real-life scenarios, it allows learners to practice and refine their skills repeatedly without risk to patients. This structured training approach not only boosts confidence but also has the potential to shorten the time required for trainees to become proficient in ERCP procedures. In summary, the Boškoski–Costamagna ERCP Trainer is a critical innovation in medical education, offering a safe, effective, and efficient way to prepare novice endoscopists for the challenges of ERCP. Its adoption in training programs can lead to better patient outcomes and improved procedural success rates.

EUS guided tissue sampling - ESGE statement

The European Society of Gastrointestinal Endoscopy (ESGE) has issued updated statements and recommendations regarding endoscopic ultrasound (EUS)-guided tissue sampling, emphasizing advancements in needle technology, sampling techniques, and specimen handling to optimize diagnostic accuracy. The key points of the ESGE statement are outlined below: ### 1. **Needle Design and Selection**: - **End-cutting Fine-Needle Biopsy (FNB) Needles**: ESGE recommends end-cutting FNB needles over reverse-bevel FNB or standard fine-needle aspiration (FNA) needles for sampling solid pancreatic lesions. This recommendation is based on evidence showing that end-cutting FNB needles provide superior tissue yield and histologic quality. - **Fine-Needle Aspiration (FNA)**: FNA remains a valuable option when rapid on-site evaluation (ROSE) is available. ROSE allows real-time assessment of sample adequacy, ensuring diagnostic accuracy during the procedure. ### 2. **Subepithelial Lesions (SELs)**: - For SELs measuring **≥20 mm**, ESGE considers both EUS-FNB and mucosal incision–assisted biopsy (MIAB) as equally effective sampling methods. - For SELs measuring **<20 mm**, MIAB may be preferred when the operator has sufficient expertise. MIAB is advantageous for smaller lesions as it allows more precise tissue acquisition. ### 3. **Infection Prevention**: - ESGE no longer recommends routine antibiotic prophylaxis before EUS-guided sampling of solid masses or during EUS-FNA of pancreatic cystic lesions. This change reflects evidence indicating a low risk of infection and the need to avoid unnecessary antibiotic use. ### 4. **Specimen Handling and Diagnostic Accuracy**: - ESGE emphasizes the importance of precision-driven sampling strategies and efficient specimen handling to improve diagnostic outcomes. Proper handling of tissue samples is critical for achieving high histologic quality and accurate diagnoses. ### 5. **Advancements in EUS Technology**: - The updated ESGE review highlights advancements in needle technology and sampling techniques, which have significantly improved the diagnostic yield and quality of EUS-guided tissue acquisition. ### Summary: The ESGE statement underscores the importance of selecting the appropriate needle type, tailoring sampling techniques to the lesion type and size, and adopting evidence-based approaches to specimen handling. These updates are aimed at improving diagnostic outcomes and minimizing unnecessary interventions, such as routine antibiotic prophylaxis, in EUS-guided tissue sampling.

Single-use therapeutic gastroscope

The single-use therapeutic gastroscope is a newly approved disposable device designed for complex therapeutic interventions in gastrointestinal endoscopy. This pilot feasibility study assessed its clinical performance during 19 therapeutic procedures, including gastrointestinal bleeding management, pancreatic necrosectomies, foreign body removals, stent placements, and cryo-balloon ablations. The device demonstrated an 84% intraprocedural technical success rate, with clinical success achieved universally when technical success was attained. However, in 16% of cases, clinicians had to switch to reusable gastroscopes due to limitations like poor visibility, suction occlusion, or inadequate scope angulation. User experience rated the device at 3.2 out of 5, reflecting moderate satisfaction. No adverse events were reported, indicating short-term safety. While the single-use gastroscope shows promise for therapeutic applications, its performance limitations and moderate usability suggest the need for further refinement. Broader studies are required to assess its long-term therapeutic reliability, visual performance, and environmental sustainability compared to reusable endoscopes.

MAPS III guideline updates

The MAPS III guideline updates, set for 2025, provide comprehensive, pragmatic, and risk-stratified recommendations for the detection, staging, treatment, and surveillance of gastric precancerous conditions and early gastric neoplasia. Below is a detailed summary of the updates: --- ### **1. Screening Recommendations:** - **Population-Level Screening:** - Endoscopic screening is suggested every **2–3 years** in high-risk regions (age-standardized incidence rate [ASR] >20 per 100,000). - In **intermediate-risk regions**, screening every **5 years** may be considered if it is cost-effective. - Screening is **not recommended** in low-risk regions. - **Individual Risk Assessment:** - Regardless of geographic origin, **individual gastric cancer risk assessment** is recommended at the time of the **first gastroscopy**. - Screening or surveillance beyond the age of **80 years** is generally discouraged, although patient-specific comorbidities should be considered when planning treatment. --- ### **2. Endoscopy and Biopsy Techniques:** - **High-Quality Endoscopy:** - Use of **virtual chromoendoscopy** (with appropriate training) is recommended for: - Detection of gastric lesions. - Targeted biopsies. - Staging of atrophic gastritis and intestinal metaplasia. - Post-therapy surveillance. - **Biopsy Strategy:** - Random biopsies are only recommended when no visible endoscopic abnormalities are detected. - Suggested biopsy sampling involves: - Two vials with **2 biopsies each** from the **antrum/incisura** and the **corpus**. - **Advanced Imaging:** - Routine advanced imaging (e.g., **EUS, CT, MRI, or PET-CT**) before endoscopic resection is **not recommended** unless: - Deep invasion is suspected. - The suitability of endoscopic resection is uncertain. --- ### **3. Treatment Recommendations:** - **Endoscopic Resection:** - **Endoscopic submucosal dissection (ESD)** is recommended for most differentiated dysplastic or intramucosal cancers, based on size and ulceration criteria. - **Endoscopic mucosal resection (EMR)** may be an option for small, low-risk lesions. - **Post-Resection Management:** - Clear histology-based pathways are outlined: - **Curative/Very Low-Risk Lesions:** Typically require no further treatment. - **Curative/Low-Risk Lesions:** May need further staging or multidisciplinary discussion. - **Local-Risk Lesions:** Favor endoscopic surveillance or re-treatment. - **High-Risk Lesions** (e.g., deep invasion, lymphovascular invasion [LVI], positive vertical margins, large/ulcerated or poorly differentiated tumors): Require staging and multidisciplinary evaluation for additional therapy. --- ### **4. Staging Systems:** - Validated endoscopic grading systems are endorsed for staging gastric precancerous conditions and neoplasia: - **Kimura–Takemoto classification.** - **EGGIM (Endoscopic Grading of Gastric Intestinal Metaplasia).** - **OLGA (Operative Link on Gastritis Assessment).** - **OLGIM (Operative Link on Gastric Intestinal Metaplasia Assessment).** --- ### **5. H. pylori Management:** - **H. pylori Eradication:** - Strongly recommended for: - Patients with precancerous conditions (e.g., atrophic gastritis or intestinal metaplasia). - Patients who have undergone therapy for gastric precancerous lesions or early gastric cancer. --- ### **6. Lifestyle and Preventive Measures:** - Patients should be advised to **stop smoking**, as it is a risk factor for gastric cancer. - **Low-dose aspirin** may be considered for cancer prevention in selected individuals who are at high cardiovascular risk. --- ### **Key Considerations:** - The guidelines emphasize **personalized risk assessment** and evidence-based approaches for surveillance and treatment. - Screening and surveillance should be **tailored to the patient's age, risk factors, and comorbidities**, with a focus on avoiding unnecessary procedures in low-risk groups or elderly patients. - The use of advanced endoscopic techniques and validated staging systems ensures the accurate detection and management of gastric precancerous conditions. --- In summary, the 2025 MAPS III guidelines aim to optimize the early detection and management of gastric precancerous conditions and early cancer through risk stratification, high-quality endoscopic techniques, and individualized care plans. These updates reflect the latest evidence and advancements in gastric cancer prevention and treatment.

Water-aided colonoscopy

Water-aided colonoscopy refers to a set of advanced techniques where water is used instead of, or in combination with, gas (such as air or carbon dioxide) during a colonoscopy procedure. These techniques aim to improve the process of colonoscope insertion, enhance visualization of the colon and its lesions, and assist in the resection (removal) of abnormal tissue like polyps or larger lesions. The three main methods under water-aided colonoscopy are **water immersion**, **water exchange**, and **underwater resection**. ### Techniques: 1. **Water Immersion**: - During insertion of the colonoscope, water is infused into the colon and left in place. - This reduces colonic distension (stretching) and prevents the formation of loops in the colon, making the procedure smoother and less uncomfortable for the patient. 2. **Water Exchange**: - Water is infused into the colon during insertion, but it is actively suctioned out along with debris and other material. - This improves the cleanliness of the colon and enhances the visibility of the mucosal (inner) surface during withdrawal, which is critical for detecting abnormalities. 3. **Underwater Resection**: - Lesions, such as polyps, are submerged in water during their removal. - This technique aids in polypectomy (removal of polyps) and advanced resections, such as UEMR (underwater endoscopic mucosal resection) or UESD (underwater endoscopic submucosal dissection). ### Utility of Water-Aided Colonoscopy: - **Improved Adenoma Detection Rates (ADR)**: Water exchange has been shown to increase the detection of adenomas (precancerous polyps), as the enhanced cleanliness and visibility of the colon's surface make it easier to identify abnormalities. - **Better Bowel Cleanliness**: Water exchange removes debris and residual stool during the procedure, resulting in a cleaner colon for examination and resection. - **Enhanced Resection Outcomes**: Underwater resection methods, such as UEMR, are associated with higher rates of en bloc resection (removing the lesion in one piece) and lower recurrence rates compared to conventional methods. - **Reduced Thermal Injury**: The water acts as a "heat sink" during procedures that use electrocautery (heat-based cutting), dissipating thermal energy and potentially reducing the risk of deep tissue injury. - **Comfort and Efficiency**: Water immersion reduces colonic stretching and loop formation, which can make the procedure more comfortable for patients and easier for the endoscopist to navigate the colon. ### Challenges: Despite its benefits, water-aided colonoscopy has barriers to widespread adoption, including longer learning curves for practitioners, additional training time, and reimbursement models that often prioritize procedural volume over outcomes. In summary, water-aided colonoscopy is an innovative approach that enhances the safety, efficiency, and diagnostic accuracy of colonoscopy procedures, particularly for detecting and removing abnormal growths in the colon.